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Abstract
The number of testing modalities available for the diagnosis of significant 
coronary artery disease has grown over the last few decades. Inappropriate uti-
lization of these tests often leads to: (i) further investigation, (ii) physician and 
patient uncertainty, (iii) harm and poor outcomes, and (iv) increase in health 
care costs. An informed approach to the evaluation of the patients with stable 
ischemic chest pain can lead to efficient use of resources and better outcomes. 
Throughout the course of this chapter, we will explain how the applications of 
age-old statistical principles are still relevant in this modern era of technological 
advancement.
Keywords: Bayes’ theorem, coronary artery disease, ischemic heart disease, 
appropriate use criteria
1. Introduction
Cardiovascular diseases (CVDs) remain a leading cause of death across the 
world [1]. Ischemic heart disease (IHD) is one of the largest contributors to these 
deaths both globally and in the United States of America [2] and contributes to 
years of productivity loss due to complications from disease sequelae. These include 
non-fatal myocardial infarction, stable angina pectoris and symptomatic ischemic 
cardiomyopathy. Although the number of deaths resulting from fatal MI has been 
decreasing, the number of quality years lost from IHD complications has been 
increasing [3]. The decrease in mortality is largely due to interventions for the 
management of acute coronary syndromes (ACS) and early percutaneous coronary 
intervention (PCI) for ST-segment elevation MI [4, 5].
There are a variety of scoring systems/tools which have been used to predict 
(with varying degrees of success), which patients are likely to have obstructive 
coronary artery disease as a cause of their chest pain [6].
The most frequently used clinical decision making tool to decide the likelihood 
of CAD on the basis of patient characteristics, is the Diamond-Forrester classifica-
tion [7]. It is derived from the application of Bayesian principles [8] and has formed 
the backbone of many of the guideline statements for the management of patients 
with suspected stable ischemic heart disease [9, 10].
Due to the limitations of the history and physical examination in determin-
ing the likelihood of disease, clinicians have utilized various testing modalities 
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to further increase certainty. Evaluation of chest pain has been no different. The 
number of available testing strategies has increased over the last few decades, and 
the technologies underlying these tests are constantly being refined. Despite the 
growing number of options, many clinicians remain unsure how to utilize these 
modalities [5, 11]. The increasing utilization of these tests often leads to: (i) further 
investigation, (ii) physician and patient uncertainty/anxiety [12], (iii) harm and 
(iv) increase in health care costs.
We aim to cover the following in our chapter review:
i. Briefly simplify the principles of Bayes’ theorem. Give a brief overview of 
the concepts of how the post-test probability of disease varies based on pre-
test likelihood and test characteristics.
ii. Review key stratification methods for the likelihood of significant CAD.
iii. Outline the test characteristics of the main functional and anatomic imaging 
modalities used in chest pain evaluation based on available evidence.
iv. Use practical examples to show how the use of low sensitivity/specificity 
testing in varying patient groups can lead to post-test uncertainty and the 
need for further testing.
v. Explain how many of the currently available appropriate use criteria guiding 
testing, conflict with Bayesian principles.
Bayes’ theorem has been previously applied in many clinical scenarios, includ-
ing the evaluation of chest pain [13–16]. This chapter will neither be burdened 
with complex statistical formulas nor difficult to follow calculations. Rather, it 
will provide a practical approach to decision making and dealing with diagnostic 
uncertainty in patients with stable chest pain. Though many of the concepts 
expressed here are not original to the authors, we hope that this review will provide 
a comprehensive approach to testing—considering patient outcomes and resource 
utilization. The almost three century old principles of the Bayesian approach to 
decision making are just as relevant today with the growing technological advance-
ments in the new era of precision medicine.
2. Bayesian approaches in clinical decision making
2.1 Clinicians and statistics
Health-care professionals at all levels of training and expertise often struggle 
with conceptualizing many statistical and probability ideas [17, 18]. Even for the 
most experienced mathematicians, the complex calculations involved in large deci-
sion making scenarios using Bayesian approaches are hard to comprehend, far less 
compute [13].
To follow Bayesian approaches in clinical decision making, it does require the 
understanding of some key statistical concepts. We hope to present this in an easy to 
follow format that is based in evidence [19].
The widely referenced Harvard Medical School cognitive experiment (see 
Appendix A) (and the research which followed) has provided much useful insight 
into how we approach probability testing. Two of these insights are:
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i. Medical professionals often fall victim to what is referred to as the “base-rate 
neglect” fallacy. Here-in they place unwarranted reliability to the outcome of a 
test—positive or negative, ignoring the relevance of prevalence in the population.
Stated differently: A positive test result for a rare disease is more likely to be 
a false positive, regardless of how well the test can detect the presence of disease 
(sensitivity). The converse is also true, that a negative test result in a population in 
which there is a very high prevalence, is more likely to be a false negative.
ii. When results are presented as frequencies rather than probabilities, they are 
easier to follow. Take this example from Fenton and colleagues [13]:
1. Out of 1 million people 1000 are likely to die from treatment A, but only 
10 are likely to die from treatment B.
Instead of:
2. The probability of dying from treatment A is 0.001, but the probability 
of dying from treatment B is 0.00001.
Before applying Bayes’ theorem to the evaluation of chest pain, we will review 
some of the key statistical and probability concepts necessary to gain an under-
standing of Bayesian approaches.
2.2 The characteristics of diagnostic tests
There are a few characteristics of diagnostic tests which are paramount to the 
understanding and use of Bayesian arguments. These include sensitivity, specificity, 
positive predictive value, negative predictive value and likelihood ratios. There are 
many factors which influence the reliability or these values.
Sensitivity and specificity are often explained in complex statistical terminol-
ogy, however, they can be defined very simply:
• Sensitivity (Sens.): The ability to pick up disease when disease is present
• Specificity (Spec.): The ability to rule out disease when there is no disease
Let us use the example of a hypothetical test designed to detect patients with 
CAD called ‘CAD Finder’. We have two Groups of patients, Groups A and B 
(Figure 1). The 100 patients in Group A have proven CAD and the 100 in Group B 
are proven to be without CAD. To measure the sensitivity of the ‘CAD Finder’ we 
use it on patients in Group A and see how many have a positive result (93%). This 
is the sensitivity of the ‘CAD Finder’ for picking up CAD. To measure specificity, 
we perform the ‘CAD Finder’ on Group B and see how many have a negative result 
(80%). This would be the specificity for the ‘CAD Finder’ for ruling out CAD. It 
should also be noticed that, 7 out of 100 patients with CAD will falsely test negative 
and 20 out of 100 without CAD will get a false positive result.
The sensitivity and specificity of any test or maneuver are usually compared to 
a “gold-standard” test. In the case of suspected coronary artery disease, that test is 
invasive coronary angiography.
In clinical practice, it is often more helpful to gauge the performance of a test 
based on the prevalence of the disease of interest. This introduces the concepts of 
positive and negative predictive value [15].
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• Positive predictive value (PPV): The ability of a test to be positive when 
disease truly is present.
• Negative predictive value (NPV): The ability of a test to be negative when 
disease truly is absent.
PPV and NPV vary inversely with the prevalence of a disease in a population. 
The relevance of this becomes apparent when tests which have been “studied” in 
a subgroup are applied in another population with different characteristics and 
disease prevalence. This brings us to our final concept worth defining:
• Likelihood ratios: “the likelihood that a given test result would be expected 
in a patient with the target disorder compared to the likelihood that that same 
result would be expected in a patient without the target disorder.” [20]
Using the formula:
LR+ = sensitivity/(1-specificity).
2.3  The importance of disease prevalence, population characteristics and cut-
off values
The reliability of a test is dependent on the prevalence of the disease of interest 
in the population in which it is studied. Bayesian methods allow us to apply known 
test characteristics to any population, once the population characteristics and 
prevalence of disease is known.
We will illustrate the outcomes when the same hypothetical test ‘CAD Finder’ 
is used in two different populations: (i) male Olympic sprinters (Table 1) and (ii) 
male elderly veterans (Table 2). Continuing with our hypothetical exercise, it is 
noted that our ‘CAD Finder’ is best at differentiating between ‘disease’ and ‘no 
disease’.
Let us say that in a population of male Olympic sprinters, 5% have significant CAD 
and 95% were without. At the cut-off point for a positive result—93% of the ‘Significant 
CAD’ disease group would test positive (true positive) but 20% of the ‘No CAD’ group 
would also test positive (false positive). If the CAD Finder is used on a population of 
10,000 similar Olympic sprinters, the outcomes would be as shown in Table 1.
Figure 1. 
Percentage of persons classified with and without CAD by the CAD finder.
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2.3.1 Performance of the ‘CAD finder’ in detecting significant CAD
When our ‘CAD Finder’ is used on our population of 10,000 Olympic sprinters, 
2365 would test positive. However, only 465 out of those 2365 (20%) truly have 
significant CAD. This means that 1900 athletes will be false positives.
Rule 1. If a disease is uncommon in a population (i.e.) low prevalence—in this 
case 5% prevalence, any positives are more likely to be false positives.
In the population of male elderly veterans 95% have significant CAD and 5% 
are without disease. The outcomes of the ‘CAD Finder’ on a population of 10,000 
similar male veterans would be depicted below in Table 2.
Out of the 1065 veterans who test negative for CAD, 665 (62%) actually have 
significant CAD. This is a large proportion of false negative results. Compare that 
to the population of Olympic sprinters where 35 out of the 7635 negative test results 
(<1%) are false negatives.
Rule 2. If a disease is highly prevalent in a population, in this case 95%, any 
negatives are more likely to be false negatives.
2.3.2 Performance of the ‘CAD finder’ in detecting persons without CAD
Since 95% of the population of athletes (9500) are truly without significant 
CAD, in the absence of any testing at all, if you told a patient in this population, 
they were without disease you would be correct most of the time. However, if we 
relied on our ‘CAD Finder’, our ability to detect athletes without CAD decreases 
from 95 to 76.3% (7635 of our Olympic sprinters test negative).
Table 2. 
Number of persons classified with ‘significant CAD’ and ‘No CAD’ by a CAD finder test among a population 
of male veterans (high prevalence population) (80% True Negatives (400); 7% False Negatives (665)).
Table 1. 
Number of persons classified with ‘significant CAD’ and ‘No CAD’ by a CAD Finder Test among a population 
of male Olympic sprinters (low prevalence population) (93% True Positives (465); 20% False Positives 
(1900)).
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This illustrates that in this population of Olympic sprinters, our CAD Finder 
test performs very unreliably despite its good characteristics (Sensitivity 93%, 
Specificity 80%).
Rule 3. A test is unreliable in picking up disease when the prevalence of disease 
in the population is less than the value of the ‘false positive rate/true positive rate’.
In our above example with the ‘CAD Finder’, the false positive/true positive 
rate = 20/93; =21%.
2.4 The Bayesian method
2.4.1 What is Bayes’ theorem
Bayes’ theorem (or more accurately Bayes’ Rule) [21] was first described 
by the 18th century Episcopal minister Thomas Bayes in an essay published in 
the Philosophical Transactions of the Royal Society of London in 1764, in which he 
describes solving a complex problem of chances involving billiard balls [22]. Since 
Bayes’ theorem was first theorized, it has been expressed in a variety of ways. We 
will use three [3] formats that are relevant to our discussion.
In mathematical terms, Bayes’ theorem is expressed as follows:
  Pr (A | X) =  
Pr (X | A) Pr (A) 
  ___________________________  
Pr (X | A) Pr (A) + Pr (X | ~A) Pr (~A) 
 
In this formula Pr(A|X) is the chance of having disease (A) given a positive test 
(X); Pr(X|A) is the chance of a positive test (X) given the presence of disease (A); 
Pr(A) is the pretest probability of the disease; Pr(~A) is the pretest probability of 
not having disease and Pr(X|~A) is the chance of a positive test (X) even if there is 
no disease (~A).
In plain English, Bayes’ theorem states: “The probability of having a disease 
based on a selected test (after the test is done), is related to the pre-test probability 
that the patient has the disease (or its prevalence) and the test’s sensitivity and 
specificity.”
In diagrammatic form (Figure 2), the posttest probability is proportional to the 
pretest probability times the likelihood of the disease in the population. This gener-
ates the simplest representation of Bayesian statistics:
3. Practical use of Bayesian principles in cardiovascular testing
Given that accurate application of Bayes’ statistics relies on the updating of 
probabilities (based on the acquisition of new evidence)—it is obvious then that 
any recommendations stated hereafter are as current as the present medical knowl-
edge and is influenced by the writers. Our aim therefore is not to provide guidelines 
Figure 2. 
Processing information using Bayes’ theorem.
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on the evaluation of patients with stable chest pain, but to convey a sense of comfort 
with using these tools, to allow the reader to generate their own informed approach 
to patient care.
There are generally two aims of performing cardiac testing in patients with 
stable chest pain (i) to determine which patients are likely to have obstructive CAD 
and (ii) to predict outcome or prognosis. In our discussion that follows, we will 
review how current testing modalities achieve either or both targets.
3.1 Determining pre-test probability in patients with stable chest pain
There are many factors which must be accounted for by the clinician when 
determining the pre-test probability of a patient (without known CAD) having 
coronary artery disease as a cause of their chest pain. These include history, patient 
characteristics, physical examination findings, physician experience, bias/heuris-
tics among others. Approaches to rule-out other cardiac and non-cardiac causes will 
not be covered here.
We will focus on only one approach (Diamond-Forrester classification) to the 
generation of pre-test probability data [7], see Tables 3 and 4. This risk prediction 
model was generated through Bayesian statistics. Other scoring methods include the 
Goldman Reilly criteria (Goldstein), Thrombolysis in Myocardial Infarction (TIMI) 
risk score and the Morise Score [23]. Although it was developed over three decades 
ago, the Diamond-Forrester classification has been validated in modern populations 
[24]. The Diamond-Forrester classification stratifies patient pretest probability on 
the basis of three clinical variables: age, gender and chest pain characteristics. It 
allows clinicians to stratify patients along a spectrum of pretest likelihoods from 2 
to 94%. For simplicity, many guideline groups have chosen to categorize patients 
in groups of very low, low, intermediate and high pretest probability (see Table 4). 
This classification of pretest probability (very low, low, intermediate and high) will 
form our basis of using Bayesian methods to select testing in patients.
3.2 Testing modalities for the evaluation of stable chest pain
The tests available for the evaluation of patients with stable chest pain can 
be divided into functional or anatomic. This is based on the type of information 
provided. The list of functional tests includes exercise ECG, stress echocardiogram, 
myocardial perfusion imaging (single-photon emission tomography (SPECT) and 
positron emission tomography (PET)) and stress MRI. The list of anatomic tests 
includes coronary CT angiography and coronary artery calcium scoring and the 
gold standard test-cardiac catheterization.
In Table 5, we have included the characteristics of the testing modalities we will 
reference throughout this chapter [23]. Please note that for each testing modality in 
Table 5, two values are reported for each test characteristic (sensitivity, specificity etc.) 
Table 3. 
Pretest likelihood of CAD in Symptomatic patients according to age and sex (combined Diamond/Forrester 
and CASS Data) [9].
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These values are based on the test’s performance when used in the overall population 
vs. in patients with suspected CAD. We already know from Bayesian principles that this 
difference is based on varying prevalence of disease in these two groups.
One important limitation of the available data is that there are no head-to-head 
trials comparing the test performance of many of the pharmacological or exercise 
testing modalities—using cardiac catheterization as a reference. Current data is 
limited to small samples sizes and the use of old techniques/technologies.
3.3 Noninvasive functional tests
It is important to make the distinction between exercise testing and ‘stress test-
ing’ which are often used synonymously. ‘Stress testing’ refers to any pharmacologi-
cal or exercise testing modality which imposes a stress on the cardiovascular system 
[25]. Many of these alternative forms of ‘stress testing’ modalities will be covered in 
the following subsections.
3.3.1 Exercise ECG
Exercise ECG testing is often the first used testing modality in the workup 
of stable chest pain [11]. It has been around for several decades and has been 
studied in many clinical scenarios. Unfortunately, it has an intermediate sensi-
tivity and specificity for the detection of CAD. Exercise testing is based on the 
premise of monitoring the cardiovascular system’s response to physiological 
stress. This is to determine clinical signs and symptoms which would not be 
present at rest.
Table 5. 
Summary of diagnostic accuracy of noninvasive tests compared with invasive coronary angiography [23].
Table 4. 
Diamond and Forrester pre-test probability of coronary artery disease by age, sex and symptoms [11].
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Exercise testing in the lab uses dynamic testing principles because (i) it can be 
graduated and (ii) it places a volume stress on the heart [25].
There are various exercise protocols available for laboratory exercise testing. The 
Bruce Protocol is most commonly used [26]. Regardless of the protocol, exercise 
capacity is graduated and measured at various “stages”. This is based on the physi-
ological principle that at a given intensity of activity, the parameters of heart rate, 
blood pressure, and cardiac output are relatively constant [27]. The quantity of 
oxygen transported and utilized in cellular metabolism is measured as V02max, 
which will be discussed in more detail later [28]. A second measurement parameter 
of oxygen utilization is myocardial oxygen uptake or Mo2. In clinical scenarios Mo2 
is estimated by the product of heart rate and systolic blood pressure (rate-pressure 
product). In healthy myocardium, there is a linear relationship between Mo2 and 
coronary vessel blood flow [25].
However, if there is either an obstruction to flow or reduction in myocardial 
cell uptake of oxygen (as in ischemia), then the Mo2 in the region will be reduced. 
The implications of this are that if there is a coronary obstruction, a point will be 
reached where there is supply/demand mismatch and signs and symptoms of isch-
emia will occur. Regardless of the form of physical activity, for any given coronary 
obstruction, angina usually occurs at the same rate-pressure product.
The rate of oxygen uptake by healthy tissue will increase with increasing 
demand until it reaches a maximal level of oxygen extraction. This is termed 
the V02max, and varies with age (and to a lesser degree with gender). It has been 
observed that increasing V02 during exercise has a linear relationship with heart 
rate until it reaches the V02max plateau. At this point, the heart rate may continue to 
increase as myocardial energy generation reverts to anaerobic metabolism. This, in 
turn, may cause signs and symptoms of ischemia, which in turn may cause a ‘false 
positive’ finding for ischemia.
Most labs use the formula, 220-Age (for either gender) to calculate a Maximal 
Predicted Heart Rate (MPHR) as a surrogate for V02max. Target heart rates for 
exercise testing are then usually set at 85–100% of MPHR. In the absence of symp-
toms, ECG changes (or any other reasons to stop the test early), the test is routinely 
stopped when the MPHR is achieved. It is therefore important to recognize that 
exercise stress tests can have a false-negative if the level of exercise does not reach 
the target but may become false-positive if it reaches above the maximum.
In general, the two common exercise methods used are either the treadmill or 
cycle ergometer. End points for exercise include: achievement of target heart rate, 
fatigue, symptoms (such as chest pain or dyspnea), significant ECG changes (such 
as ST segment depressions or elevations), significant dysrhythmias, drop of systolic 
blood pressure (usually >10 mmHg), patient request or inability to continue.
The diagnosis of ischemia is usually made from chest pains and/or development 
of horizontal or down-sloping ST segment deviations of ≥1 mm during exercise 
or the recovery period. Other ECG criteria, such as the development of a bundle 
branch block (especially LBBB) may suggest ischemia (but are less sensitive).
In addition to evaluation for ischemia, the exertional capacity and hemody-
namic responses to stress testing have additional prognostic value [26]. One of the 
more popular ways to evaluate this is with the Duke Treadmill Score (DTS), which 
incorporates exertional capacity, ECG changes and symptom onset (Exercise minutes 
(Bruce) − (ST deviation in mm X 5) − (angina index X 4)) [29].
There are several limitations to standard exercise stress testing. Firstly, it is lim-
ited by a patient’s ability to exercise and achieve the target heart rate. Additionally, 
any baseline ECG abnormalities, such as left bundle branch block, left ventricular 
hypertrophy with repolarization abnormalities, ST segment depression and ventric-
ular pre-excitation, further reduces the test’s specificity and even sensitivity [26].
Differential Diagnosis of Chest Pain
10
The use of image testing as an adjunct to exercise testing, improves both sen-
sitivity and specificity. Imaging with the use of pharmacologic agents can also be 
useful in patients who cannot ambulate or have baseline ECG abnormalities limiting 
interpretation. Currently, the most commonly used stress imaging modalities are 
echocardiography and nuclear imaging.
3.3.2 Stress echocardiography
Stress echocardiography (SE) is reliant on the identification of wall motion and 
wall thickening abnormalities. Generally, patients undergo echo acquisitions prior 
to exercise and immediately after exercise (or, in patients who exercise on supine 
bicycles, at peak exercise). The images are compared between rest and stress for 
changes in wall motion, wall thickening and left ventricular sized and function. 
Sensitivities for SE are about 88%, with a specificity of 89%.
The major advantages of SE are availability, absence of radiation exposure and 
cost. However, it has been reported to have lower sensitivity than radionuclide 
imaging, especially in single vessel disease detection [30]. It is also operator depen-
dent and image quality is limited by patient characteristics (e.g. COPD and obesity). 
When used with exercise testing, it is limited by the patient’s ability to get into posi-
tion for scanning quickly after peak exercise (typically, the patient must get off the 
treadmill, get in the correct position on the bed and the sonographer must acquire 
good images in four different views—all within 1 min).
For patients who cannot walk, dobutamine stress echocardiography (DSE) 
has been shown to offer similar sensitivity and specificity to SE for the detection 
of obstructive CAD. However, because it does not involve exercise, the additional 
prognostic data offered by exercise protocols (e.g. using the Duke Treadmill Score) 
are not available with DSE.
3.3.3 Nuclear imaging testing
There are two forms of radionuclide imaging modalities currently available for 
chest pain evaluation: single-photon emission tomography (SPECT) and positron 
emission tomography (PET). Both rely on the use of radiotracer isotopes to detect 
areas of ischemia or infarct. There are two types of SPECT radiotracers commonly 
used in clinical settings: technetium (Tc-99m)-labeled tracers and thallium (Tl-
201). PET imaging uses the more high-energy rubidium (Rb)-82 radiotracer. The 
physical and physiological principles behind how radiotracers elements are used to 
evaluate for CAD is beyond the scope of this chapter. We will focus on the perfor-
mance characteristics of both nuclear tests and a few pertinent advantages and 
disadvantages.
3.3.3.1 SPECT
SPECT imaging can be used in conjunction with exercise or pharmacologic 
agents to assess for CAD. When SPECT is used with exercise protocols, it provides 
similar functional capacity and ECG data as exercise ECG, with the added sensitiv-
ity and specificity provided by imaging. It is the more commonly used and more 
readily available of the radionuclide modalities.
Pharmacologic stress images are most commonly obtained with vasodilat-
ing agents (adenosine, dipyridamole and regadenoson). The vasodilating agents 
either differently or indirectly stimulate the A2A (adenosine) receptors leading to 
coronary arteriolar vasodilation. Vasodilating agents are suitable for use in patients 
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who cannot exercise, where significant increases in heart rate are not desired (e.g. 
patients with permanent pacemaker devices or left bundle branch block) or patients 
who have had recent acute coronary syndromes. Sensitivity and specificities for 
these are between 83–84% and 79–85% respectively.
SPECT is a great alternative to stress echocardiography, when patient’s char-
acteristics prevent good imaging windows [30, 31]. It has a number of important 
limitations. Since it is dependent on radiotracer delivery to tissue, in patients with 
equally compromised flow in all coronary vessels (triple vessel disease), there is 
risk for a false negative study—due to so-called ‘balanced ischemia’. Soft tissue and 
uptake by other organs (e.g.) gallbladder can also limit image quality and often 
cause false positive findings [23].
3.3.3.2 PET
PET imaging uses the more high-energy rubidium (Rb)-82 radiotracer. This 
allows for less displacement by soft tissue and potentially fewer false positives. PET 
has the additional advantage of being combined with CT imaging. This allows for 
soft-tissue attenuation correction (to reduce false positives) and assessment of 
coronary artery calcium (which will be discussed later).
The major disadvantage of PET is the shorter half-life of radiotracer and its cost. 
As a result, its availability is limited.
3.4 Noninvasive anatomic tests
3.4.1 Coronary CT angiography (CCTA)
Coronary CT angiography allows for non-invasive assessment of coronary artery 
disease [32]. Intravenous contrast agents within the lumen of coronary vessels 
facilitate visual calculation of obstruction/stenosis. Newer CT techniques use a 
64-multislide (or better) acquisition hardware to obtain images. Available post-
processing software packages further refine images.
The definition of ‘significant coronary artery disease’ (CAD) with CT coronary 
angiography is ≥70% diameter stenosis of at least one major epicardial artery seg-
ment or ≥50% diameter stenosis in the left main coronary artery [33]. The presence 
of collateral coronary supply as well as low at-risk myocardium can render high 
degree stenotic lesions asymptomatic. For this reason, the degree of CAD obstruc-
tion correlates poorly with symptoms and limits its usefulness for determining the 
cause of chest pain.
The presence of coronary calcium causes artifacts during imaging that may 
obscure the coronary lumen. For this reason, CCTA is often combined with assess-
ment of coronary calcium to make predictions about outcomes or prognosis [34]. 
Novel techniques such as fractional flow reserve derived from CT (FFRCT) are being 
used to determine whether stenotic lesions are physiologically significant [35]. 
FFRCT is beyond the scope of discussion here.
Although CCTA allows for rapid imagining, it has limited utility in patients 
with rapid heart rates, arrhythmias, renal impairment. It also carries radiation 
exposure risk.
3.4.2 Coronary artery calcium scoring (CACS)
CACS is obtained using non-contrast CT scanning. Post-processing algorithms 
are used to quantify the degree of coronary vessel calcification. The three most 
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common scoring methods are Agatston, volume and mass. CAC scoring has been in 
formal use since 1990 [36]. Although traditionally it has been recommended for use 
in asymptomatic patients, it has been shown to provide similar predictive reliability 
as functional testing, especially when used with other CT modalities [37].
Evidence suggests that a positive CAC is more sensitive than functional testing at 
predicting MACE. Alternatively, an abnormal functional test result is more specific. 
Increasing the cut-off point of a ‘positive’ CAC improves specificity at the expense 
of sensitivity [38]. This is a consequence of the Bayesian principles we discussed. 
However, it has little usefulness in determining the cause of chest pain.
3.5 Bayesian approach to test selection
Using the Diamond-Forrester classification, there are three broad categories 
of patients with stable chest pain that a clinician will likely encounter. These are 
grouped as ‘low pretest probability—5%’, ‘intermediate pre-test probability—
approx. 50%’ and ‘high pre-test probability—95%’. In the following three subsec-
tions we will explore strategies of using Bayesian approaches to testing in each of 
these groups.
There are many factors which will influence real life decisions on which tests 
to order and when. Some of these are patient characteristics (ability to exercise), 
resource availability, institutional culture, and the degree of uncertainty a clinician/
patient is comfortable with accepting.
Bayesian approaches allow us to make informed decisions on sequential test 
selection. Tests assessing CAD by the same markers should not be duplicated. To 
avoid this, one potential way of classifying testing modalities would be: (i) tests 
that identify ischemia via surface changes—(e.g. stress ECG), (ii) tests that identify 
ischemia via nuclear tracer, (iii) tests that identify ischemia via wall motion abnor-
malities—(e.g. stress echocardiography) [15].
3.5.1 Test selection in patients with low and high pre-test probability
We know from ‘Rule 1’ that in a population with low prevalence, any positive 
result is likely to be a false positive. This means that in this scenario (low pretest 
probability) if one opts not to perform any cardiac testing, because you suspect the 
patient does not have CAD, you would be correct most of the time. ‘Rule 3’ stated 
that “If a disease is highly prevalent in a population, any negatives are more likely 
to be false negatives”. We also learnt in Section 2 that when testing is performed 
in this group, the possibility of true positive results does not improve much on no 
testing at all. If one opted to assume that every patient in this group (high pretest 
probability) had significant CAD and went ahead with a definitive test/treatment 
(i.e. ICA), one would be correct most of the time, and may avoid an unnecessary 
interim test.
3.5.2 Test selection in patients with intermediate pre-test probability
The intermediate pre-test probability group is where Bayesian approaches 
yield the greatest benefit. This is also where informed sequential testing can be 
very informative and efficient if used correctly. It is impossible for us to illustrate 
the relative outcomes of all possible combinations of testing here. We will use two 
examples to illustrate how tests with varying sensitivities and specificities can give 
different post-test probabilities when used in high (Patient A), low (Patient B) or 
intermediate pre-test probability patients (Patient C).
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Patient A has very high pre-test probability of disease (95%).
Patient B has very low pre-test probability of disease (5%).
Patient C has an intermediate probability of disease (50%).
Example 1. A test has a sensitivity of 90% and specificity 90% (e.g. nuclear 
imaging testing).
• Patient A (with 95% pre-test probability):
 ○ Chance a + test will mean + disease= >99%
 ○ Chance a − test will mean + disease = 68%
• Patient B (with 5% pre-test probability):
 ○ Chance a + test will mean + disease = 32%
 ○ Chance a − test will mean + disease = <1%
• Patient C (with 50% pre-test probability):
 ○ Chance a + test will mean + disease = 90%
 ○ Chance a − test will mean + disease = 10%
Example 2. A test has a sensitivity of 65% and specificity 65% (e.g. Exercise 
ECG testing).
• Patient A (95% pre-test probability):
 ○ Chance a + test will mean + disease = 97%
 ○ Chance a − test will mean + disease = 91%
• Patient B (5% pre-test probability):
 ○ Chance a + test will mean + disease = 9%
 ○ Chance a − test will mean + disease = 3%
• Patient C (50% pre-test probability):
 ○ Chance a + test will mean + disease = 65%
 ○ Chance a − test will mean + disease = 35%
The decision on when to stop testing or proceed with further evaluation based 
on post-test certainty, is highly individualized. It is based on the post-test value 
at which one thinks a disease has been either sufficiently ‘ruled-in’ or ‘ruled-out’. 
Generally, most a pre-test or post-test probability of ≤15% or ≥85% would be 
considered reasons to stop further testing—and either assume no disease when the 
probability is ≤15% or assume disease when the probability is ≥85%.
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4. Appropriate use criteria and the delivery of high-value care
Technological advancement has resulted in a growing number of available 
testing modalities that offer increased sensitivity and specificity [39]. This rapid 
growth has led to an increase in healthcare expenditure. Payers were the first 
to respond to this growth by implementing restrictions to regulate expenditure 
through strict criteria for reimbursement and prior authorization requirement.
In response, clinician led groups developed Appropriate Use Criteria (AUC) 
to improve efficient utilization of these testing modalities [40]. The American 
College of Cardiology (ACC) along with other organizations have developed 
AUC documents to aide with decision making for cardiac testing. The first 
statement of this kind was for the efficient utilization of myocardial perfusion 
imaging in 2005 [41]. Subsequently, AUC documents have classified indications 
for the use of: CCTA, echocardiography (including stress), cardiac magnetic 
resonance among others.
AUC documents are distinct from clinical guideline/recommendation state-
ments. Appropriate use is classified based on the ratio of possible benefit versus 
the potential harm of a procedure with an eye to ‘cost-effectiveness’. The defini-
tion of “an appropriate diagnostic or therapeutic procedure is one in which the 
expected clinical benefit exceeds the risks of the procedure by a sufficiently wide 
margin, such that the procedure is generally considered acceptable or reasonable 
care” [40].
AUC are scored from 1 to 9 and classified into three broad categories: ‘rarely 
appropriate care’ (score 1–3), ‘may be appropriate care’ (score 4–6) and ‘appropri-
ate care’ (score 7–9). The Bayesian criticism of these AUC statements is that they 
are often not based on evidence but rather on aims to reduce healthcare expenditure 
based on the availability of less costly, safe alternatives.
5.  Review of the current recommendations for the evaluation of stable 
ischemic heart disease (SIHD)
The use of functional testing (both exercise and pharmacological) has long been 
favored as the preferred modality of ischemia evaluation [10]. The main reasons are: 
(i) that applying increasing workload on the heart more closely mimics the patho-
physiology of supply/demand mismatch, (ii) exercise capacity provides incremen-
tal diagnostic and prognostic information and finally, and (iii) cost-effectiveness.
Since the advent of exercise stress testing, many alternative diagnostic modali-
ties have become available. As was previously mentioned, most of these testing 
modalities have not been compared to each other in head-to-head trials. The 
Bayesian criticism of much of the available evidence is that limited data regarding 
pretest clinical stratification or how posttest classification contributed to decision 
making is reported [42].
The biggest questions of the last decade have been whether (i) bypassing testing 
is a viable/safe option in select low risk patient groups, and (ii) if anatomic testing is 
as good as or a better alternative to traditional functional testing [37, 43]. It would be 
counterproductive to review all the guideline recommendations and AUC here since 
they are frequently revised and there are many competing agencies that produce them. 
Instead, we will just highlight a few which either follow or contradict the Bayesian 
method to give the reader a better understanding of some of their limitations.
In patients with low pretest probability and at low risk it is reasonable to exclude 
the diagnosis of stable angina on clinical assessment alone and defer further diag-
nostic testing [33]. This is supported by Bayesian argument. The decision to defer 
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testing is highly individual and will be guided by physician experience and shared 
decision making with patients.
The AUCs recommend exercise ECG as the initial testing modality in most 
patient populations [9–11]. We have previously showed the potential pitfalls of 
low sensitivity and specificity testing in either low or high probability patients. For 
this reason we do not recommend that exercise ECG testing be used alone to either 
exclude or diagnose significant CAD as a cause of stable chest pain, no matter the 
pretest probability [33]. However, exercise testing is still recommended because of 
the valuable prognostic information it provides (with the use of Duke Treadmill 
Score, etc.). This leads to the other bit of contradictory recommendations in the 
area of stress echocardiography in low pretest groups—where a patient’s ability to 
exercise downgrades stress echocardiography testing from ‘appropriate’ to ‘inappro-
priate’ [44]. Presumably, the AUC feels that a regular ECG exercise test is preferable 
in these patients, contrary to Bayesian arguments.
When the pretest probability of disease is very high, any testing is likely to result 
in a false negative. Bayesian methods argue for proceeding with definitive testing/
intervention. However, even in this patient population invasive coronary angi-
ography is usually a second or third-line option after other non-invasive tests are 
inconclusive [9, 33].
The anatomic testing modalities have high sensitivity. Nevertheless, they are 
regarded as rarely appropriate across all patient groups by current AUC [11]. On 
the other hand, the current NICE guidelines recommend offering 64-slice CCTA as 
a first testing modality in patients with typical angina. The recommendations for 
Heartflow FFRCT are less clear [45].
The final question remains, what is regarded as ‘confirmatory’. This varies with 
clinician comfort and experience. Some guidelines suggest that a posttest probabil-
ity of >85% is sufficient to confirm the diagnosis of significant CAD [15].
6. Limitations of the Bayesian approach
One of the major limitations of the use of the Bayesian method is its reliance 
on pre-test probability (some advocates of Bayesian approaches consider this to 
be a strength). Many critics have stated that this results in ‘subjectivity’ on which 
inferences of post-test outcomes are based [42]. We have already stated some of the 
many factors which contribute to variations in pre-test estimates at the individual 
clinician level. This point just reiterates the importance of scrutinizing the quality 
of evidence on which conclusions are based. Other proponents of the Bayesian 
approach have therefore stressed the need to base pre-test probability on sound 
reasoning and evidence and to combine available data to reach consensus [42].
7. Conclusions
Bayesian analysis is very important in the evaluation of patients with stable isch-
emic chest pain. Even with the use of a simplified assessment tool of pretest prob-
abilities, one can maximize efficiency of test selection, lower costs and improve 
patient outcomes.
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 Appendices and Nomenclature
“One in thousand people have a prevalence for a particular heart disease. There 
is a test to detect this disease. The test is 100% accurate for people who have the 
disease, and is 95% accurate for those who do not (this means that 5% of people 
who do not have the disease will be wrongly diagnosed as having it). If a randomly 
selected person tests positive what is the probability that the person actually has 
the disease?”
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